Medicine:S-268019
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
S-268019-b is a protein subunit COVID-19 vaccine candidate developed by Shionogi.[1][2]
A study in non-human primates published in 2022 concluded S-268109-b demonstrated efficacy in a SARS-CoV-2 challenge experiment, although neutralizing antibodies against the Omicron variant were reduced.[3]
In a phase 1/2 clinical trial in Japan, the developers concluded reactions to the vaccine were mild, and neutralizing antibodies were similar to those in people who had recovered from Covid-19.[4] A phase 3 trial planned for 54,915 participants began in December 2021 in Vietnam.[5]
Preliminary results of a phase 2/3 trial using S-268019-b as a booster dose after two doses of the BNT162b2 vaccine by Pfizer concluded the vaccine was non-inferior to a booster dose of BNT162b2.[6]
References
- ↑ "Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 21 March 2021.
- ↑ "A Phase 2/3 Study of S-268019". jrct.niph.go.jp. Japan Registry of Clinical Trials. Retrieved 20 October 2021.
- ↑ "Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys". Vaccine 40 (31): 4231–4241. July 2022. doi:10.1016/j.vaccine.2022.05.081. PMID 35691872.
- ↑ "Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings". Vaccine 40 (27): 3721–3726. June 2022. doi:10.1016/j.vaccine.2022.04.054. PMID 35606235.
- ↑ A Phase 3, Randomized, Observer-Blind, Placebo- Controlled Cross-over Study to Evaluate the Efficacy, Safety, and Immunogenicity of S-268019 for the Prevention of COVID-19. National Institutes of Health. 26 July 2022. https://clinicaltrials.gov/ct2/show/NCT05212948. Retrieved 19 September 2022.
- ↑ "Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study". Vaccine 40 (32): 4328–4333. July 2022. doi:10.1016/j.vaccine.2022.06.032. PMID 35738968.
 |
